Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382549 · ClinicalTrials.gov registry record · Early Phase 1
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
A Early Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02382549: Clinical Trial Early Phase 1 study, sponsored by Craig L Slingluff, Jr.
NCT02382549 is a Early Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02382549, a Early Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by performing tests in the laboratory on participants' blood and tumor samples.
Interventions
- BIOLOGICAL 6MHP
- DRUG BRAF inhibitor
- DRUG MEK inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-04 |
| Est. Completion | 2022-02-28 |
| Phase | Early Phase 1 |
Why NCT02382549 stopped before completion
NCT02382549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which 6MHP is the first listed.
NCT02382549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02382549 about?
NCT02382549 is a clinical study titled "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib". This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by ...
What is the current status of trial NCT02382549?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2016-04. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT02382549?
The interventions under investigation include: 6MHP (BIOLOGICAL), BRAF inhibitor (DRUG), MEK inhibitor (DRUG).
Who is sponsoring clinical trial NCT02382549?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02382549's enrollment target sits among peer trials
8 1782nd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia